Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.
Gucalp A, Zhou XK, Cook ED, Garber JE, Crew KD, Nangia JR, Bhardwaj P, Giri DD, Elemento O, Verma A, Wang H, Lee JJ, Vornik LA, Mays C, Weber D, Sepeda V, O'Kane H, Krasne M, Williams S, Morris PG, Heckman-Stoddard BM, Dunn BK, Hudis CA, Brown PH, Dannenberg AJ. Gucalp A, et al. Among authors: brown ph. Cancer Prev Res (Phila). 2018 Apr;11(4):203-214. doi: 10.1158/1940-6207.CAPR-17-0354. Epub 2018 Feb 16. Cancer Prev Res (Phila). 2018. PMID: 29453232 Free PMC article. Clinical Trial.
The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH. Kong G, et al. Among authors: brown ph. Cancer Res. 2005 Apr 15;65(8):3462-9. doi: 10.1158/0008-5472.CAN-03-2912. Cancer Res. 2005. PMID: 15833882
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology. Visvanathan K, et al. J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470930 Free PMC article.
Tumor-suppressor activity of RRIG1 in breast cancer.
Zhang G, Brewster A, Guan B, Fan Z, Brown PH, Xu XC. Zhang G, et al. Among authors: brown ph. BMC Cancer. 2011 Jan 25;11:32. doi: 10.1186/1471-2407-11-32. BMC Cancer. 2011. PMID: 21266059 Free PMC article.
Targeting the HER/EGFR/ErbB family to prevent breast cancer.
Howe LR, Brown PH. Howe LR, et al. Among authors: brown ph. Cancer Prev Res (Phila). 2011 Aug;4(8):1149-57. doi: 10.1158/1940-6207.CAPR-11-0334. Cancer Prev Res (Phila). 2011. PMID: 21816844 Free PMC article. Review.
351 results